NEW YORK (GenomeWeb) – Thermo Fisher Scientific, GlaxoSmithKline, and Pfizer are collaborating to develop a universal next-generation sequencing-based oncology test for solid tumors that will serve as a companion diagnostic for several drug programs, Thermo said today.
Following development and validation, Thermo Fisher plans to submit the test to the US Food and Drug Administration for premarket approval, as well as to other regulatory agencies.